Introduction levels in both control and SIRT4 overexpressing cells (Fig 1G) . Thus together, our data 145 demonstrates that SIRT4 positively regulates TORC1 signalling, which is sensitive to rapamycin.
146
Although, TORC1 has several downstream target proteins, emerging literature indicates that 147 phosphorylation could be highly specific based on both substrate affinities and extent of activation 148 (34, 35) . Hence, we wanted to check if SIRT4-dependent activation of TORC1 led to 149 phosphorylation of 4E-BP1, a translation repressor protein and ULK-1, which is involved in 150 autophagy. We were surprised to find that while SIRT4-dependent TORC1 activation led to an 151 increase in pS6K (Fig 1E, S2A) and pULK (S757) levels (Fig S2B) , phosphorylation of 4E-BP1 was 152 unaltered (Fig S2C) . Although intriguing, it is now well established that 4E-BP1 is a preferred 153 substrate of TORC1 and whereas its phosphorylation is resistant to Rapamycin treatment (33),
154
complete starvation leads to a loss of p4E-BP1. These suggest that while minimal TORC1 activity is 155 sufficient to phosphorylate 4E-BP1 (possibly maximally), phosphorylation of substrates like S6K is 156 dependent on extent of mTOR activation.
157
Consistent with the results described above, knock down of SIRT4 led to a significant 158 decrease in TORC1 signalling . Here again, phosphorylation of 4E-159 BP1 remained unaltered, similar to when SIRT4 was ectopically expressed, indicating differential 160 effect with regards to SIRT4-dependent control of TORC1 (Figs S2F) . Importantly, TORC1 161 signalling was drastically reduced in primary hepatocytes from SIRT4 -/-mice when compared to the 162 controls ( Fig 1H) . Furthermore, restoring SIRT4 expression in primary hepatocytes derived from
163

SIRT4
-/-mice increased pS6K to levels comparable to controls, indicating rescue of TORC1 164 signalling (Figs 1H and S1D) . These experiments using knock down or knockout of SIRT4 not only ruled out the possibility of overexpression-based artefacts, but clearly established SIRT4 as a key 166 determinant of TORC1 signalling.
167
Even though until now SIRT4-dependent control of TORC1 was unknown, mTOR has been 168 previously shown to negatively regulate Sirt4 expression. But it should be noted that, this was 169 shown in cancer cells (29) and it is unlikely to apply to normal physiological contexts. Importantly,
170
SIRT4 protein levels and TORC1 signalling are highest under nutrient excess or fed states, across 171 cells and tissues (2, 20, 25) . Hence, given that both are induced in a fed state it is difficult to 172 envisage a negative interaction between these factors under normal physiological conditions.
173
Nonetheless, we wanted to check if mTOR inhibition affected Sirt4 mRNA levels in primary 174 hepatocytes. Unlike in cancer cells (29), we did not find Sirt4 expression to be altered in response to 175 Rapamycin ( Fig S2H) . These results clearly demonstrate that mitochondrial SIRT4 is a positive 176 regulator of TORC1 signalling in non-cancerous cells/tissues. glucose conditions exhibit a robust decrease in pS6K, which was rescued upon SIRT4 expression 186 (Fig 2B) , and this was reminiscent of control-transfected cells grown in low glucose containing media (Fig 2A) . These results clearly indicated that while ectopic expression of SIRT4 mimics 188 mTORC1 signalling under a high nutrient state, its knockdown phenocopied signalling in low 189 glucose conditions.
190
Next, given that nutrients and growth factors in the serum are potent activators of mTOR, we 191 wanted to assess the interplay between serum/amino-acid inputs and SIRT4 in regulating TORC1 192 signalling. As expected, serum-and amino acid-deprivation led to a stark decrease in TORC1 193 signalling in both control and SIRT4 transfected cells (Fig 2C) . Despite this decrease, we noticed 194 that pS6K levels were still higher in SIRT4 transfected cells following serum-and amino acid- 
SIRT4-dependent glutamine sparing mediates TORC1 activation
204
It was striking to note the similarity between the glutamine-mediated increase in TORC1 205 signalling under high glucose and in a SIRT4-dependent response under low glucose (Fig 1) 
219
Towards this, we first checked if the observed effects of SIRT4 on TORC1 were because of 220 altered glutamine channelling into the TCA cycle, specifically under low glucose conditions. As 221 expected, we found that glutamine supplementation led to elevated ɑ-KG levels, which was 222 accompanied by a small increase in TORC1 signalling in control cells (Fig 3C) . α-KG levels did not 223 decrease upon SIRT4 overexpression in low glucose containing media without glutamine 224 supplementation, nonetheless this led to activation of TORC1 (Fig 3C) . However, it is important to 225 note that unlike in control cells, while a-KG levels did not increase in SIRT4 transfected cells 226 following glutamine supplementation, phosphorylation of S6K was significantly higher (Fig 3C) .
227
Thus, the reciprocal changes in glutamine utilization and extent of S6K phosphorylation, which was 228 dependent upon SIRT4 expression, clearly indicated that differential channelling of glutamine into 229 TCA cycle regulated TORC1 in the cytosol (Fig 3C and D) . These findings were corroborated by 230 enhanced GDH activity in primary hepatocytes from SIRT4 -/-mice, which was reduced to control levels when SIRT4 expression was restored (Fig 3F, S4B and C Together with the results presented in Fig 3A and 3B , the additive increase in pS6K 239 following glutamine and SIRT4 supplementation suggested that SIRT4-mediated control of TORC1 240 was also dependent upon another cue. We have earlier established that in the absence of SIRT4, 
242
AMPK is an upstream inhibitor of TORC1 (37). Thus, we wanted to assess whether SIRT4-243 mediated inhibition of AMPK also contributed to TORC1 activation. Activation of AMPK by 244 AICAR led to a drastic reduction in pS6K in both control and SIRT4 over expressing cells (Fig. 245 3G), and this decrease was not rescued by glutamine supplementation. Conversely, inhibiting 246 AMPK in SIRT4 KO hepatocytes using compound-C led to an increase in pS6K levels. Importantly,
247
this was further enhanced upon SIRT4 rescue (Fig. S4E) conditions, which was rescued upon SIRT4 expression (Fig 4A, C) . Importantly, there was a marked 258 increase in mTOR intensity on the lysosomes in glutamine supplemented SIRT4 overexpressing 259 cells (Fig 4B-C) . These not only corroborated the biochemical data but also confirmed that SIRT4 On assessing the ratio of LC3-II to LC3-I, an indicator of autophagy, we saw a significant 291 decrease in LC-II/LC3-I in SIRT4 over expressing cells (Fig 5E) . Conversely, there was a robust 292 increase in LC3-II/LC3-I ratio in SIRT4 knockdown cells (Fig 5F) . While LC3-II/LC3-I ratio is 293 indicative of extent of autophagy, it is not confirmatory. As established, we checked the autophagy 294 flux by treating cells with leupeptin, which inhibits lysosomal proteases (40), and assaying for LC3-cells under low glucose conditions ( Fig 5G) . Interestingly, ectopic expression of SIRT4 under low 297 glucose conditions dampened this response ( Fig 5H) and was comparable to autophagy flux of 298 control transfected cells grown in media containing high glucose (Fig 5I) . On the other hand,
299
knocking down SIRT4 expression in cells grown in high glucose media led to a significant increase 300 in LC3-II (Fig 5J) , which was similar to control transfected cells under low glucose conditions (Fig   301   5G ). These clearly indicated that presence or absence of SIRT4 affected cellular autophagy and 302 mimicked either a fed or fasted state, respectively and was consistent with change in TORC1 303 signalling (Fig 2) .
304
In the context of autophagy, AMPK and TORC1 counteract each other by phosphorylating 305 the common downstream substrate ULK1. Notably, TORC1 mediated inhibitory phosphorylation of 306 ULK1 at Ser-757 (pULK757) has been shown to prevent AMPK-dependent activatory 307 phosphorylation at Ser-317/777 (41). Thus, the effects of SIRT4 on autophagy are consistent with 308 changes in the levels of pULK757 (Fig S2B and S2E ).
309
To get another correlate of SIRT4-dependent effects on cellular physiology, we scored for 310 cell proliferation, which is again inherently linked with AMPK and mTOR activities (42). As 311 anticipated while cells expressing SIRT4 were more proliferative (Figs 5K, and S1A), knocking 312 down SIRT4 led to reduced proliferation, as compared to respective controls (Figs 5L and S1B).
313
This was again consistent with the ability of SIRT4 to induce anabolic-signalling with TORC1.
Discussion
318
Catabolic and anabolic pathways/processes are intrinsically dependent upon the ability of 319 cells to sense nutrient availability and have been largely studied under deprivation conditions.
320
However, if and how intracellular utilization of one macronutrient affects the ability of the other to 321 impinge on metabolic signalling is relatively less understood. Specifically, glutamine is utilized via 322 anaplerotic pathways under starvation (43) and is also known to activate mTOR signalling (17, 18 conclusive mechanistic support to explain both glutamine sparing-mediated and SIRT4-dependent 372 activation of TORC1. Moreover, based on our earlier study wherein we had identified SIRT4 to be a 373 negative regulator of AMPK and the results described here, we show that SIRT4 controls TORC1 374 via both AMPK and glutamine. This is interesting since glutamine utilization is intrinsically coupled 375 to cellular energetics, as mentioned earlier (31). Therefore, it is likely that glutamine sparing and 376 mitochondrial ATP production, which affects AMPK signalling, might synergistically bring about 377 multiple dynamic states of mTOR/TORC1 activation.
378
Emerging literature indicates that both extent of TORC1 activation and differential 379 phosphorylation of downstream substrates are crucial for encoding specificity (33, 35, 44) . In this 380 regard, it is interesting to note that SIRT4-mediated control of mTOR is limited to TORC1-381 dependent phosphorylation of S6K and ULK1 but not 4E-BP1. It should be noted that Kang et al 382 reported that 4E-BP1, a high affinity substrate, is also resistant to TORC1 inhibition (33, 34), analogous to our findings. Hence, it will be exciting to address, in the future, the differential control 384 of mTOR-dependent processes by mitochondrial signals, and the impact on cellular growth and 385 proliferation.
386
Our study also distinguishes the cross-talk between metabolic inputs, SIRT4 functions and (Sigma Aldrich Cat. No# C3867) coated plates. Media was changed to serum free medium after 6 415 hours of plating. All animal studies were performed using IAEC approved protocols.
416
Plasmids and constructs: Human SIRT4 cDNA was cloned into pBabe-puro. pLKO.1-eGFP 417 scrambled shRNA was a gift from Sorab Dalal (ACTREC, India). pLKO.1 Sirt4 shRNA 418 (TRC0000018948) was purchased from Sigma Aldrich. SIRT4 was cloned into pAdtrack CMV 419 plasmid, which was a gift from Bert Vogelstein (Addgene plasmid # 16405).
420
Adenoviral and lentiviral preparation: SIRT4 was cloned into pAdtrack CMV plasmid and 421 adenovirus was prepared as per the protocol described by Luo et al., 2007 (45) . Cells were collected Cat. No# SML0601) was used at a concentration of 20μM for 1 hour in low (5mM) glucose media.
442
For experiments under low/high glucose, cells were either shifted to 5mM glucose containing media TBST for 1 hour at RT followed by washes in TBST. Next, the membranes were visualized using 466 the GE AI600 chemiluminescence system with ECL reagent from Thermo Scientific (Cat.
467
No#1859023/185022). were lysed using assay buffer provided in the kit and centrifuged at 13000 rpm for 3-5 minutes at 501 4°C. For ɑ-KG, lysates were further deproteinized using perchloric acid and then processed as per 502 manufacturer's instructions. Both assays were set up in 96-well plates and colorimetric readings 503 taken using Tecan Infinite M200 pro plate reader system at 570 nm for ɑ-KG and 450nm for GDH. 
